Bing Xiong's Laboratory

Publications

Here are some of our recent publications:

2025

• Li N, Wang L, Hu X, Xu H, Yang B, Zhan L, Cai Y, Gu Y, Chen X, Zheng Y, Liu T, Gao Z, Xiong B. Conformational restriction enables discovering a series of chroman derivatives as potent and selective NaV1.8 inhibitors with improved pharmacokinetic properties. Eur J Med Chem. 2025 May 6;293:117697. doi: 10.1016/j.ejmech.2025.117697. Epub ahead of print. PMID: 40347793.
• Zhou Y, Wang L, Ren R, Zhang J, Huan X, Yang P, Miao ZH, Xiong B, Wang Y, Liu T. Structure-Based Discovery of a Series of Novel MAT2a Inhibitors. ACS Med Chem Lett. 2025 Mar 15;16(4):646-650. doi: 10.1021/acs.jmedchem.4c03069. Epub 2025 Feb 26. PMID: 40011026.
• Shi L, Xu Z, Chen X, Meng Q, Zhou H, Xiong B, Zhang N. Sertraline and Astemizole Enhance the Deubiquitinase Activity of USP7 by Binding to Its Switching Loop Region. J Med Chem. 2025 Mar 13;68(5):5874-5890. doi: 10.1021/acs.jmedchem.5c00032. Epub 2025 Feb 25. PMID: 39999290.
• Yang Y, Liu H, Yuan H, Lyu K, Zhong H, Li Y, Cao D, Zhao W, Zhang H, Xiong B, Chen D, Guo D. Design of Selective BRD4 Inhibitors for the Treatment of Autosomal Dominant Polycystic Kidney Disease. J Med Chem. 2025 Mar 13;68(5):5257-5274. doi: 10.1021/acs.jmedchem.4c02128. Epub 2025 Feb 13. PMID: 39945752.
• Zhang J, Liu B, Ren R, Song S, Bao X, Huan X, Li H, Xu J, Yu T, Wang R, Miao ZH, Xiong B, He J, Liu T. Discovery and Optimization of a Series of Novel Morpholine-Containing USP1 Inhibitors. J Med Chem. 2025 Feb 13;68(3):3673-3699. doi: 10.1021/acs.jmedchem.4c02792. Epub 2025 Feb 4. PMID: 39902599.
• Lyu K, Ren Y, Mou J, Yang Y, Pan Y, Zhang H, Li Y, Cao D, Chen L, Chen D, Guo D, Xiong B. Structure-Based Rational Design and Evaluation of BET-Aurora Kinase Dual-Inhibitors for Treatment of Cancers. J Med Chem. 2025 Jan 23;68(2):1344-1364. doi: 10.1021/acs.jmedchem.4c01933. Epub 2024 Dec 31. PMID: 39844725.

2024

• Jiang H, Li C, Li N, Sheng L, Wang J, Kan WJ, Chen Y, Zhao D, Guo D, Zhou YB, Xiong B, Li J, Liu T. Optimization and Biological Evaluation of Novel 1H-Pyrrolo[2,3-c]pyridin Derivatives as Potent and Reversible Lysine Specific Demethylase 1 Inhibitors for the Treatment of Acute Myelogenous Leukemia. J Med Chem. 2024 Dec 26;67(24):22080-22103. doi: 10.1021/acs.jmedchem.4c02017. Epub 2024 Dec 4. PMID: 39630953.
• Luo M, Ye Y, Tang L, Kan W, Chen L, Li C, Sheng L, Zhou Y, Li J, Xiong B, Wang H, Chen D. Design and development of a series of 4-(piperazin-1-yl)pyrimidines as irreversible menin inhibitors. Eur J Med Chem. 2024 Dec 15;280:116918. doi: 10.1016/j.ejmech.2024.116918. Epub 2024 Sep 30. PMID: 39366253.
• Che T, Zhang W, Cheng X, Lv S, Zhang M, Zhang Y, Yang T, Nan W, Wan S, Zeng B, Li J, Xiong B, Zhang J. Structural mechanism of human HCN1 hyperpolarization-activated channel inhibition by ivabradine. J Biol Chem. 2024 Nov;300(11):107798. doi: 10.1016/j.jbc.2024.107798. Epub 2024 Sep 20. PMID: 39307309; PMCID: PMC11530593.
• Wang D, Sun D, Wang X, Peng X, Ji Y, Tang L, He Q, Chen D, Yang Y, Zhou X, Xiong B, Ai J. Remodeling tumor-associated macrophage for anti-cancer effects by rational design of irreversible inhibition of mitogen-activated protein kinase-activated protein kinase 2. MedComm (2020). 2024 Jul 10;5(7):e634. doi: 10.1002/mco2.634. PMID: 38988492; PMCID: PMC11233931.
• Li H, Liu BJ, Xu J, Song SS, Ba R, Zhang J, Huan XJ, Wang D, Miao ZH, Liu T, He JX, Xiong B. Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidin-7(8H)-one derivatives as potent USP1 inhibitors. Eur J Med Chem. 2024 Sep 5;275:116568. doi: 10.1016/j.ejmech.2024.116568. Epub 2024 Jun 14. PMID: 38889606.
• Yu B, Lu Q, Li J, Cheng X, Hu H, Li Y, Che T, Hua Y, Jiang H, Zhang Y, Xian C, Yang T, Fu Y, Chen Y, Nan W, McCormick PJ, Xiong B, Duan J, Zeng B, Li Y, Fu Y, Zhang J. Cryo-EM structure of human HCN3 channel and its regulation by cAMP. J Biol Chem. 2024 Jun;300(6):107288. doi: 10.1016/j.jbc.2024.107288. Epub 2024 Apr 16. PMID: 38636662; PMCID: PMC11126801.
• Chen Y, Wang Z, Zhang J, Shi Q, Yang H, Deng Y, Wang X, Liu T, Geng M, Xiong B, Huang X. Structure-based discovery of a new series of nucleoside-derived ring-opening PRMT5 inhibitors. Eur J Med Chem. 2024 Mar 5;267:116171. doi: 10.1016/j.ejmech.2024.116171. Epub 2024 Jan 28. PMID: 38301329.
• Chen YH, Lv H, Shen N, Wang XM, Tang S, Xiong B, Ding J, Geng MY, Huang M. Correction to: EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells. Acta Pharmacol Sin. 2024 May;45(5):1093-1094. doi: 10.1038/s41401-023-01208-1. Erratum for: Acta Pharmacol Sin. 2020 Feb;41(2):270-277. doi: 10.1038/s41401-019-0268-y. PMID: 38228911; PMCID: PMC11053107.

2023

• Song L, Cao J, Chen L, Du Z, Zhang N, Cao D, Xiong B. Screening and optimization of phage display cyclic peptides against the WDR5 WBM site. RSC Med Chem. 2023 Aug 17;14(10):2048-2057. doi: 10.1039/d3md00288h. PMID: 37859722; PMCID: PMC10583817.
• Zhang J, Li Y, Tang H, Zhou Q, Tong L, Ding J, Xie H, Xiong B, Liu T. Design and synthesis of 1H-pyrazolo[3,4-d]pyrimidine derivatives as hematopoietic progenitor kinase 1 (HPK1) inhibitors. Bioorg Chem. 2023 Nov;140:106811. doi: 10.1016/j.bioorg.2023.106811. Epub 2023 Aug 26. PMID: 37659145.
• Chen X, Cao D, Liu C, Meng F, Zhang Z, Xu R, Tong Y, Xin Y, Zhang W, Kang W, Bao Q, Shen J, Xiong B, You Q, Jiang Z. Discovery of 1H-Imidazo[4,5-b]pyridine Derivatives as Potent and Selective BET Inhibitors for the Management of Neuropathic Pain. J Med Chem. 2023 Jul 13;66(13):8725-8744. doi: 10.1021/acs.jmedchem.3c00372. Epub 2023 Jun 29. PMID: 37382379.
• Zhou D, Xu Z, Huang Y, Wang H, Zhu X, Zhang W, Song W, Gao T, Liu T, Wang M, Shi L, Zhang N, Xiong B. Structure-based discovery of potent USP28 inhibitors derived from Vismodegib. Eur J Med Chem. 2023 Jun 5;254:115369. doi: 10.1016/j.ejmech.2023.115369. Epub 2023 Apr 11. PMID: 37075624.
• Fu K, Xu W, Yang R, Zhao H, Xu H, Wei Y, Liu H, Qiu Y, Chen D, Guo D, Xiong B. 2,6-diazaspiro[3.4]octan-7-one derivatives as potent sigma-1 receptor antagonists that enhanced the antinociceptive effect of morphine and rescued morphine tolerance. Eur J Med Chem. 2023 Mar 5;249:115178. doi: 10.1016/j.ejmech.2023.115178. Epub 2023 Feb 1. PMID: 36753922.
• Shi H, Tang H, Li Y, Chen D, Liu T, Chen Y, Wang X, Chen L, Wang Y, Xie H, Xiong B. Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors. Eur J Med Chem. 2023 Feb 15;248:115064. doi: 10.1016/j.ejmech.2022.115064. Epub 2022 Dec 30. PMID: 36621137.
• Fan T, Ji Y, Chen D, Peng X, Ai J, Xiong B. Design, synthesis and biological evaluation of 4-aminoquinoline derivatives as receptor-interacting protein kinase 2 (RIPK2) inhibitors. J Enzyme Inhib Med Chem. 2023 Dec;38(1):282-293. doi: 10.1080/14756366.2022.2148317. PMID: 36408835; PMCID: PMC9683047.

2022

• Yang B, Zhang H, Li N, Gao L, Jiang H, Kan W, Yuan H, Li J, Zhao D, Xiong B, Zhou Y, Guo D, Liu T. Discovery of Novel N-(5-(Pyridin-3-yl)-1H-indazol-3-yl)benzamide Derivatives as Potent Cyclin-Dependent Kinase 7 Inhibitors for the Treatment of Autosomal Dominant Polycystic Kidney Disease. J Med Chem. 2022 Dec 8;65(23):15770-15788. doi: 10.1021/acs.jmedchem.2c01334. Epub 2022 Nov 17. PMID: 36384292.
• Chen Y, Shi Q, Yang H, Li J, Zhou K, Zhang J, Wang Z, Shi H, Xiong B, Liu J, Huang X, Liu T. Structure-activity relationship study of a series of nucleoside derivatives bearing sulfonamide scaffold as potent and selective PRMT5 inhibitors. Bioorg Chem. 2023 Jan;130:106228. doi: 10.1016/j.bioorg.2022.106228. Epub 2022 Nov 4. PMID: 36356371.
• Wang N, Yang Y, Wen J, Fan XR, Li J, Xiong B, Zhang J, Zeng B, Shen JW, Chen GL. Molecular Determinants for the High-Affinity Blockade of Human Ether-à-go-Go-Related Gene K + Channel by Tolterodine. J Cardiovasc Pharmacol. 2022 Nov 1;80(5):679-689. doi: 10.1097/FJC.0000000000001336. PMID: 35881423.
• Wang Q, Tang B, Sun D, Dong Y, Ji Y, Shi H, Zhou L, Yang Y, Luo M, Tan Q, Chen L, Dong Y, Li C, Xie R, Zang Y, Shen J, Xiong B, Li J, Chen D. Discovery of 4-cyclopropyl-3-(2-((1-cyclopropyl-1H-pyrazol-4-yl) amino) quinazolin-6-yl)-N-(3-(trifluoromethyl) phenyl) benzamides as potent discoidin domain receptor inhibitors for the treatment of idiopathic pulmonary fibrosis. Acta Pharm Sin B. 2022 Apr;12(4):1943-1962. doi: 10.1016/j.apsb.2021.11.012. Epub 2021 Nov 17. PMID: 35847490; PMCID: PMC9279635.
• Luo M, Wu Q, Yang Y, Sun L, Huan X, Tian C, Xiong B, Miao Z, Wang Y, Chen D. Design and development of a novel series of oral bivalent BET inhibitors with potent anticancer activities. Eur J Med Chem. 2022 Sep 5;239:114519. doi: 10.1016/j.ejmech.2022.114519. Epub 2022 Jun 11. PMID: 35714446.
• Li N, Yang H, Liu K, Zhou L, Huang Y, Cao D, Li Y, Sun Y, Yu A, Du Z, Yu F, Zhang Y, Wang B, Geng M, Li J, Xiong B, Xu S, Huang X, Liu T. Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors. J Med Chem. 2022 Jul 14;65(13):9459-9477. doi: 10.1021/acs.jmedchem.2c00709. Epub 2022 Jun 15. PMID: 35704853.
• Sun Y, Tang H, Wang X, Feng F, Fan T, Zhao D, Xiong B, Xie H, Liu T. Identification of 1H-pyrazolo[3,4-b]pyridine derivatives as novel and potent TBK1 inhibitors: design, synthesis, biological evaluation, and molecular docking study. J Enzyme Inhib Med Chem. 2022 Dec;37(1):1411-1425. doi: 10.1080/14756366.2022.2076674. PMID: 35587686; PMCID: PMC9132415.
• Dong Y, Tang BX, Wang Q, Zhou LW, Li C, Zhang X, Sun DD, Sun X, Zhang XM, Xiong B, Li J, Shi H, Chen DQ, Zang Y. Discovery of a novel DDRs kinase inhibitor XBLJ-13 for the treatment of idiopathic pulmonary fibrosis. Acta Pharmacol Sin. 2022 Jul;43(7):1769-1779. doi: 10.1038/s41401-021-00808-z. Epub 2021 Nov 24. PMID: 34819618; PMCID: PMC9253339.

2021

• Zhang Z, Guo Z, Xu X, Cao D, Yang H, Li Y, Shi Q, Du Z, Guo X, Wang X, Chen D, Zhang Y, Chen L, Zhou K, Li J, Geng M, Huang X, Xiong B. Structure-Based Discovery of Potent CARM1 Inhibitors for Solid Tumor and Cancer Immunology Therapy. J Med Chem. 2021 Nov 25;64(22):16650-16674. doi: 10.1021/acs.jmedchem.1c01308. Epub 2021 Nov 15. PMID: 34781683.
• Jiang Y, Peng X, Ji Y, Dai Y, Fang Y, Xiong B, Ren W, Hu Y, Chen Y, Ai J. The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G₁ Cell-Cycle Arrest through c-Myc Downregulation. Mol Cancer Ther. 2021 Nov;20(11):2198-2206. doi: 10.1158/1535-7163.MCT-21-0127. Epub 2021 Sep 13. PMID: 34518294.
• Xiong B. Allosteric Modulation: Dynamics is Double-"E"dged. J Med Chem. 2021 Apr 8;64(7):3694-3696. doi: 10.1021/acs.jmedchem.1c00473. Epub 2021 Mar 24. PMID: 33761250.
• Li MZ, Meng T, Song SS, Bao XB, Ma LP, Zhang N, Yu T, Zhang YL, Xiong B, Shen JK, Miao ZH, He JX. Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers. Invest New Drugs. 2021 Oct;39(5):1213-1221. doi: 10.1007/s10637-021-01096-4. Epub 2021 Mar 12. PMID: 33710464.
• Cao J, Fan T, Li Y, Du Z, Chen L, Wang Y, Wang X, Shen J, Huang X, Xiong B, Cao D. Phage-Display Based Discovery and Characterization of Peptide Ligands against WDR5. Molecules. 2021 Feb 25;26(5):1225. doi: 10.3390/molecules26051225. PMID: 33668971; PMCID: PMC7956166.
• Liu Y, Xue M, Cao D, Qin L, Wang Y, Miao Z, Wang P, Hu X, Shen J, Xiong B. Multi-omics characterization of WNT pathway reactivation to ameliorate BET inhibitor resistance in liver cancer cells. Genomics. 2021 May;113(3):1057-1069. doi: 10.1016/j.ygeno.2021.02.017. Epub 2021 Mar 2. PMID: 33667649.
• Wu Q, Chen DQ, Sun L, Huan XJ, Bao XB, Tian CQ, Hu J, Lv KK, Wang YQ, Xiong B, Miao ZH. Novel bivalent BET inhibitor N2817 exhibits potent anticancer activity and inhibits TAF1. Biochem Pharmacol. 2021 Mar;185:114435. doi: 10.1016/j.bcp.2021.114435. Epub 2021 Feb 1. PMID: 33539817.
• Yang B, Wu Q, Huan X, Wang Y, Sun Y, Yang Y, Liu T, Wang X, Chen L, Xiong B, Zhao D, Miao Z, Chen D. Discovery of a series of 1H-pyrrolo[2,3-b]pyridine compounds as potent TNIK inhibitors. Bioorg Med Chem Lett. 2021 Feb 1;33:127749. doi: 10.1016/j.bmcl.2020.127749. Epub 2020 Dec 24. PMID: 33340663.

2017-2020

• Lv K, Chen W, Chen D, Mou J, Zhang H, Fan T, Li Y, Cao D, Wang X, Chen L, Shen J, Pei D, Xiong B. Rational Design and Evaluation of 6-(Pyrimidin-2-ylamino)-3,4-dihydroquinoxalin-2(1H)-ones as Polypharmacological Inhibitors of BET and Kinases. J Med Chem. 2020 Sep 10;63(17):9787-9802. doi: 10.1021/acs.jmedchem.0c00962. Epub 2020 Aug 26. PMID: 32787081.
• Guo Z, Zhang Z, Yang H, Cao D, Xu X, Zheng X, Chen D, Wang Q, Li Y, Li J, Du Z, Wang X, Chen L, Ding J, Shen J, Geng M, Huang X, Xiong B. Design and Synthesis of Potent, Selective Inhibitors of Protein Arginine Methyltransferase 4 against Acute Myeloid Leukemia. J Med Chem. 2019 Jun 13;62(11):5414-5433. doi: 10.1021/acs.jmedchem.9b00297. Epub 2019 Jun 4. PMID: 31117515.
• Wei P, Liu B, Wang R, Gao Y, Li L, Ma Y, Qian Z, Chen Y, Cheng M, Geng M, Shen J, Zhao D, Ai J, Xiong B. Discovery of a series of dimethoxybenzene FGFR inhibitors with 5H-pyrrolo[2,3-b]pyrazine scaffold: structure-activity relationship, crystal structural characterization and in vivo study. Acta Pharm Sin B. 2019 Mar;9(2):351-368. doi: 10.1016/j.apsb.2018.12.008. Epub 2018 Dec 26. PMID: 30972282; PMCID: PMC6437634.
• Wang X, Su M, Li Y, Liu T, Wang Y, Chen Y, Tang L, He YP, Ding X, Yu F, Shen J, Li J, Zhou Y, Chen YL, Xiong B. Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor. Bioorg Med Chem Lett. 2019 Mar 15;29(6):844-847. doi: 10.1016/j.bmcl.2019.01.017. Epub 2019 Jan 18. PMID: 30713023.
• Wang Q, Dai Y, Ji Y, Shi H, Guo Z, Chen D, Chen Y, Peng X, Gao Y, Wang X, Chen L, Jiang Y, Geng M, Shen J, Ai J, Xiong B. Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma. Eur J Med Chem. 2019 Feb 1;163:671-689. doi: 10.1016/j.ejmech.2018.12.015. Epub 2018 Dec 7. PMID: 30572178.
• Chen D, Chen Y, Lian F, Chen L, Li Y, Cao D, Wang X, Chen L, Li J, Meng T, Huang M, Geng M, Shen J, Zhang N, Xiong B. Fragment-based drug discovery of triazole inhibitors to block PDEδ-RAS protein-protein interaction. Eur J Med Chem. 2019 Feb 1;163:597-609. doi: 10.1016/j.ejmech.2018.12.018. Epub 2018 Dec 11. PMID: 30562696.
• Jiang A, Liu Q, Wang R, Wei P, Dai Y, Wang X, Xu Y, Ma Y, Ai J, Shen J, Ding J, Xiong B. Structure-Based Discovery of a Series of 5H-Pyrrolo[2,3-b]pyrazine FGFR Kinase Inhibitors. Molecules. 2018 Mar 19;23(3):698. doi: 10.3390/molecules23030698. PMID: 29562726; PMCID: PMC6017193.
• Hu J, Wang Y, Li Y, Cao D, Xu L, Song S, Damaneh MS, Li J, Chen Y, Wang X, Chen L, Shen J, Miao Z, Xiong B. Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups. Eur J Med Chem. 2018 Apr 25;150:156-175. doi: 10.1016/j.ejmech.2018.02.070. Epub 2018 Feb 24. PMID: 29525435.
• Ai J, Chen Y, Peng X, Ji Y, Xi Y, Shen Y, Yang X, Su Y, Sun Y, Gao Y, Ma Y, Xiong B, Shen J, Ding J, Geng M. Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models. Mol Cancer Ther. 2018 Apr;17(4):751-762. doi: 10.1158/1535-7163.MCT-17-0368. Epub 2017 Dec 13. PMID: 29237805.
• Liu T, Xie W, Li C, Ren H, Mao Y, Chen G, Cheng M, Zhao D, Shen J, Li J, Zhou Y, Xiong B, Chen YL. Preparation of 5'-deoxy-5'-amino-5'-C-methyl adenosine derivatives and their activity against DOT1L. Bioorg Med Chem Lett. 2017 Nov 15;27(22):4960-4963. doi: 10.1016/j.bmcl.2017.10.019. Epub 2017 Oct 10. PMID: 29050780.
• Hu J, Wang Y, Li Y, Xu L, Cao D, Song S, Damaneh MS, Wang X, Meng T, Chen YL, Shen J, Miao Z, Xiong B. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor. Eur J Med Chem. 2017 Sep 8;137:176-195. doi: 10.1016/j.ejmech.2017.05.049. Epub 2017 May 27. PMID: 28586718.
• Chen L, Chen D, Tang L, Ren J, Chen J, Zhen X, Liu YC, Zhang C, Luo H, Shen J, Xiong B. Design and optimization of purine derivatives as in vivo active PDE10A inhibitors. Bioorg Med Chem. 2017 Jul 1;25(13):3315-3329. doi: 10.1016/j.bmc.2017.04.019. Epub 2017 Apr 13. PMID: 28462841.
• Zhang Y, Liu H, Zhang Z, Wang R, Liu T, Wang C, Ma Y, Ai J, Zhao D, Shen J, Xiong B. Discovery and Biological Evaluation of a Series of Pyrrolo[2,3-b]pyrazines as Novel FGFR Inhibitors. Molecules. 2017 Apr 5;22(4):583. doi: 10.3390/molecules22040583. PMID: 28379191; PMCID: PMC6154558.
• He JX, Wang M, Huan XJ, Chen CH, Song SS, Wang YQ, Liao XM, Tan C, He Q, Tong LJ, Wang YT, Li XH, Su Y, Shen YY, Sun YM, Yang XY, Chen Y, Gao ZW, Chen XY, Xiong B, Lu XL, Ding J, Yang CH, Miao ZH. Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution. Oncotarget. 2017 Jan 17;8(3):4156-4168. doi: 10.18632/oncotarget.13749. PMID: 27926532; PMCID: PMC5354820.